Archer Aviation Inc vs Eli Lilly And Co — how do they compare? Archer Aviation Inc trades at $6.42 (market cap $5.23B), while Eli Lilly And Co trades at $1,205.92 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 206.5× Archer Aviation Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Archer Aviation Inc pays none. Which is the better fit depends on your goals.
| ACHR | LLY | |
|---|---|---|
Market Cap | $5.23B | $1.08T |
Sector | Industrials | Health |
52-Week High | $13.64 | $1.24K |
52-Week Low | $4.44 | $639.43 |
Enterprise Value | $3.79B | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $6.41, up 2.4% today, with a bullish technical signal from moving averages. The stock shows strong analyst support (78% buy ratings) amid recent news of a strategic Boeing deal to acquire three businesses, boosting its defense and AI aviation portfolio. However, fundamentals remain weak with a P/S ratio of 719.85 and deeply negative profit margins, as the company is pre-revenue and burning cash to develop its eVTOL technology.
Outlook hinges on successful commercialization of air taxis and integration of Boeing assets, offering growth potential but carrying high execution risk. Investors face substantial losses until revenue scales, with net income margin at -11,590% in 2026. The Boeing partnership provides a cash flow bridge via defense revenue, yet dilution from equity offerings and regulatory delays pose near-term headwinds.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →